Form 4: Nuvation Bio Director Cui Xiangmin Reports Conversion of Preferred Stock and Exercise of Warrants Following Merger

Director Cui Xiangmin reports the conversion of Series A Preferred Stock to Class A Common Stock and the exercisability of warrants following the satisfaction of the Convertibility Condition related to the AnHeart Therapeutics merger.

Summary

• Xiangmin Cui, a director of Nuvation Bio Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions related to the conversion of Series A Preferred Stock into Class A Common Stock and the exercisability of warrants.
• These changes occurred following the satisfaction of the Convertibility Condition on September 3, 2024, which was linked to stockholder approval of the issuance of Class A common stock upon conversion of the Series A Preferred Stock and exercise of Warrants.
• The Series A Preferred Stock was automatically converted to Class A common stock at a ratio of 100 shares of Class A common stock for each share of Series A Preferred Stock, effective September 4, 2024.
• The warrants became exercisable for Class A common stock at an exercise price of $11.50, also effective September 4, 2024.
• The reported transactions involve securities held indirectly through Decheng Capital China Life Sciences USD Fund III, L.P., Decheng Capital Global Healthcare Fund (Master), LP, and Decheng Anbio Limited.
• Cui Xiangmin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing detailing expected conversions and exercises following a merger. It doesn't inherently convey positive or negative sentiment, but the completion of the merger and subsequent actions are generally viewed as a positive step.

Industry Context

This filing reflects the completion of a significant corporate event (the merger with AnHeart Therapeutics) and the subsequent conversion of securities, which is a common occurrence in such transactions. It indicates the progression of the merged entity and the realization of certain conditions outlined in the merger agreement.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders and large shareholders, as mandated by the SEC.
• The conversion of preferred stock and warrant exercises are typical steps following a merger or acquisition, especially when certain conditions are met.
• The specific terms of the conversion ratio and warrant exercise price are unique to the agreement between Nuvation Bio and AnHeart Therapeutics, and would need to be compared to similar deals to assess their favorability.

Stakeholder Impact

• Shareholders may experience a change in the number of outstanding shares of Class A Common Stock due to the conversion of preferred stock and potential exercise of warrants.
• The conversion and exercise could impact the company's capital structure.

Key Dates